Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019 July 31, 2019
Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019 June 24, 2019
Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland June 12, 2019
Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio; Reports First Quarter 2019 Financial Results and Operational Progress May 22, 2019
